Additionally, a phase-II trial is ongoing combining nivolumab with BO-112 (polyI:C dsRNA), a Toll-like receptor 3 (TLR3) agonist that has been shown to suppress MDSCs and enhance the T-cell response to the tumor in preclinical settings (NCT04420975) [91]. The gene discussed is TLR3; the disease is neoplasm.